17 May 2012
A division of Cancer Research UK is planning to study a new drug combination in the hope of thwarting the onset of lung cancer.
The disease is currently the second most common form of cancer in the UK, with Cancer Research UK detailing that there were 41,428 new cases of the condition in 2009 alone.
In order to bring this figure down in the years to come, the health organisation's Drug Development Office has opened an investigation into a drug combination for treating the disease.
The research will involve patients with advanced solid tumours being studied alongside a subset of people with non-small cell lung cancer.
Many are set to see the effects of cancer treatment that involves a drug combining two compounds which aim to starve problematic tumours while also blocking cancer cell growth.
Dr Denis Talbot, a consultant medical oncologist at Oxford University Hospitals NHS Trust and Cancer Research UK clinician at The University of Oxford, is the chief investigator of the study.
He pointed out: "Therapies for lung cancer often become ineffective because the disease becomes resistant to treatment, so we're delighted to launch this trial to test a new approach that we hope will help people with this common disease."
Posted by Edward Bartel
Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.